Lilly CMO David Hyman On The Company’s Drive To Take ‘Ambitious Swings’ In R&D

Phase III Orforglipron Obesity Data Due In 2025

 
• By Mandy Jackson
  
Lilly hopes for some Phase III homeruns in oncology, obesity and beyond in 2025 (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Leadership